Spelling suggestions: "subject:"stenosis"" "subject:"estenosis""
101 |
Bases génétiques de la sténose valvulaire aortique calcifiéeEyendja, christian 12 1900 (has links)
La sténose valvulaire aortique (SVA) est une valvulopathie résultant en l'ouverture incomplète de la valve aortique. La calcification des feuillets associée au vieillissement est la cause la plus importante de la SVA. Sa pathogénèse implique des dépôts de lipoprotéines, de l'inflammation et de la calcification des feuillets. Notre étude vise à identifier les gènes associés à une prédisposition à la SVA afin de mieux comprendre les mécanismes sous-jacents à cette maladie et potentiellement identifier de nouvelles cibles thérapeutiques.
Pour ce faire, nous avons recruté 190 patients avec SVA dégénérative et 192 témoins, appariés pour l'âge et le sexe, puis effectué une étude d’association par gènes candidats en utilisant des marqueurs génétiques polymorphiques (SNP). Les gènes candidats choisis incluent (1) ceux dont les polymorphismes ont été présumés associés à la SVA dans des études antérieures (APOB, APOE, ESR1, PTH et VDR) (2) des gènes dont les polymorphismes ont été significativement associés et validés pour quelques maladies inflammatoires (IL-10, TNFAIP3) ou pour le métabolisme lipidique (PCSK9, LDLR) dans des études d’association pangénomiques, et (3) des gènes impliqués dans la pathogénie de la SVA à partir d’études faites sur des modèles animaux en lien avec la calcification (BMP2, CCR5, CTGF, LRP5, MSX2, WNT3), le remodelage tissulaire (CTSS, MMP9) ou le métabolisme lipidique (SMPD1). Pour les gènes des groupes (1) et (2), nous avons utilisé les SNPs rapportés dans la littérature comme étant significativement associés. Pour le groupe (3), nous avons effectué une approche par «tagSNP» qui consiste à sélectionner un groupe de SNP capturant la variabilité génétique dans la région ciblée. Au total, 81 SNPs dans 18 gènes ont été testés. Nous avons trouvé une association nominale avec les gènes BMP2 (OR = 1.55, IC95%: 1.14-2.10, p = 0.004) et LRP5 (OR = 1.47, IC95%: 1.06-2.03, p = 0.023) après ajustement pour la maladie coronarienne.
Les gènes BMP2 et LRP5, impliqués dans la calcification selon certains modèles expérimentaux, sont donc associés à la SVA. Ce travail devrait être validé dans une cohorte indépendante plus large dans un avenir rapproché et il pourrait être étendu à d’autres gènes. / Aortic valve stenosis (AVS) is a valvular heart disease caused by calcification leading to incomplete opening of the aortic valve. Calcification of valve leaflets associated with aging is the most common cause of AVS. AVS pathogenesis involves lipoprotein deposits, chronic inflammation and calcification of the aortic valve leaflets. Our study aims to identify genes associated with AVS in order to better understand its mechanisms and potentially identify new therapeutic targets.
We recruited 190 cases with AVS of different severity and 192 controls matched for age and sex. Then we conducted a candidate gene association study using single nucleotide polymorphisms (SNPs). The candidate genes selected include: (1) those with polymorphisms putatively implicated in previous genetic association studies of AVS (APOB, APOE, ESR1, PTH and VDR); (2) those with validated associations to inflammatory diseases (IL-10, TNFAIP3) or lipid metabolism (LDLR ,PCSK9) in genome-wide association studies and, (3) genes impliated in AVS pathogenesis from studies with animal models and thought to be involved in calcification (BMP2, CCR5, CTGF, LRP5, MXS2, WNT3); tissue remodeling (CTSS, MMP9) or lipid metabolism (SMPD1). For the first two categories of genes, we tested the SNPs reported to be associated in the literature and, in the third category we used a tag-SNP approach which consists of selecting a subset of SNPs to capture variability in the target region. Finally, 81 SNPs in 18 genes were tested. We found a nominal association of BMP2 (OR=1.55, CI: 1.14 – 2.10, p=0.004) and LRP5 (OR=1.47, CI: 1.06 – 2.03, p=0.023) with presence of AVS after adjustment for coronary heart disease.
The genes BMP2 and LRP5, which are known to be involved in calcification based on animal models, are associated with AVS. The result of the current study should be validated in a larger independent cohort in the near future and then, it could also be extended to the study of other genes.
|
102 |
Bases génétiques de la sténose valvulaire aortique calcifiéeEyendja, christian 12 1900 (has links)
La sténose valvulaire aortique (SVA) est une valvulopathie résultant en l'ouverture incomplète de la valve aortique. La calcification des feuillets associée au vieillissement est la cause la plus importante de la SVA. Sa pathogénèse implique des dépôts de lipoprotéines, de l'inflammation et de la calcification des feuillets. Notre étude vise à identifier les gènes associés à une prédisposition à la SVA afin de mieux comprendre les mécanismes sous-jacents à cette maladie et potentiellement identifier de nouvelles cibles thérapeutiques.
Pour ce faire, nous avons recruté 190 patients avec SVA dégénérative et 192 témoins, appariés pour l'âge et le sexe, puis effectué une étude d’association par gènes candidats en utilisant des marqueurs génétiques polymorphiques (SNP). Les gènes candidats choisis incluent (1) ceux dont les polymorphismes ont été présumés associés à la SVA dans des études antérieures (APOB, APOE, ESR1, PTH et VDR) (2) des gènes dont les polymorphismes ont été significativement associés et validés pour quelques maladies inflammatoires (IL-10, TNFAIP3) ou pour le métabolisme lipidique (PCSK9, LDLR) dans des études d’association pangénomiques, et (3) des gènes impliqués dans la pathogénie de la SVA à partir d’études faites sur des modèles animaux en lien avec la calcification (BMP2, CCR5, CTGF, LRP5, MSX2, WNT3), le remodelage tissulaire (CTSS, MMP9) ou le métabolisme lipidique (SMPD1). Pour les gènes des groupes (1) et (2), nous avons utilisé les SNPs rapportés dans la littérature comme étant significativement associés. Pour le groupe (3), nous avons effectué une approche par «tagSNP» qui consiste à sélectionner un groupe de SNP capturant la variabilité génétique dans la région ciblée. Au total, 81 SNPs dans 18 gènes ont été testés. Nous avons trouvé une association nominale avec les gènes BMP2 (OR = 1.55, IC95%: 1.14-2.10, p = 0.004) et LRP5 (OR = 1.47, IC95%: 1.06-2.03, p = 0.023) après ajustement pour la maladie coronarienne.
Les gènes BMP2 et LRP5, impliqués dans la calcification selon certains modèles expérimentaux, sont donc associés à la SVA. Ce travail devrait être validé dans une cohorte indépendante plus large dans un avenir rapproché et il pourrait être étendu à d’autres gènes. / Aortic valve stenosis (AVS) is a valvular heart disease caused by calcification leading to incomplete opening of the aortic valve. Calcification of valve leaflets associated with aging is the most common cause of AVS. AVS pathogenesis involves lipoprotein deposits, chronic inflammation and calcification of the aortic valve leaflets. Our study aims to identify genes associated with AVS in order to better understand its mechanisms and potentially identify new therapeutic targets.
We recruited 190 cases with AVS of different severity and 192 controls matched for age and sex. Then we conducted a candidate gene association study using single nucleotide polymorphisms (SNPs). The candidate genes selected include: (1) those with polymorphisms putatively implicated in previous genetic association studies of AVS (APOB, APOE, ESR1, PTH and VDR); (2) those with validated associations to inflammatory diseases (IL-10, TNFAIP3) or lipid metabolism (LDLR ,PCSK9) in genome-wide association studies and, (3) genes impliated in AVS pathogenesis from studies with animal models and thought to be involved in calcification (BMP2, CCR5, CTGF, LRP5, MXS2, WNT3); tissue remodeling (CTSS, MMP9) or lipid metabolism (SMPD1). For the first two categories of genes, we tested the SNPs reported to be associated in the literature and, in the third category we used a tag-SNP approach which consists of selecting a subset of SNPs to capture variability in the target region. Finally, 81 SNPs in 18 genes were tested. We found a nominal association of BMP2 (OR=1.55, CI: 1.14 – 2.10, p=0.004) and LRP5 (OR=1.47, CI: 1.06 – 2.03, p=0.023) with presence of AVS after adjustment for coronary heart disease.
The genes BMP2 and LRP5, which are known to be involved in calcification based on animal models, are associated with AVS. The result of the current study should be validated in a larger independent cohort in the near future and then, it could also be extended to the study of other genes.
|
103 |
Multiparametric cardiovascular magnetic resonance for the assessment of cardiac function and metabolism in hypertrophy and heart failureMahmod, Masliza January 2013 (has links)
Both hypertrophied and failing hearts are characterised by pathological left ventricular (LV) remodelling, impaired myocardial energy status and alteration in substrate metabolism. Cardiac magnetic resonance imaging (CMR) and magnetic resonance spectroscopy (MRS) are powerful tools in the characterisation of these disease conditions. More recent techniques have allowed assessment of myocardial steatosis using <sup>1</sup>H-MRS and tissue oxygenation using blood oxygen level dependent (BOLD) CMR. In hypertrophy and heart failure, studies on steatosis and the relationship with other parameters such as myocardial function and fibrosis, especially in humans are limited. I therefore investigated the presence of steatosis in severe aortic stenosis (AS) and dilated cardiomyopathy (DCM), and further assessed its relation to contractile function. This study found that myocardial triglyceride (TG) content is increased in both symptomatic and asymptomatic AS patients (lipid/water ratio 0.89±0.42% in symptomatic AS; 0.75±0.36% in asymptomatic AS vs. controls 0.45±0.17%, both p<0.05) and DCM patients (lipid/ratio 0.64±0.44% vs. controls 0.40±0.13%, p=0.03). Circumferential strain was lower in both AS (-16.4±2.5% in symptomatic AS; -18.9±2.9% in asymptomatic AS vs. controls 20.7±2.0%, both p<0.05) and DCM patients (-12.3±3.4% vs. controls -20.9±1.7%, p<0.001). In AS, myocardial contractility is related to the degree of steatosis, and were both reversible following aortic valve replacement (AVR), lipid/water ratio 0.92±0.41% vs. pre AVR 0.45±0.17%, p=0.04 and circumferential strain -17.2±2.0% vs. pre AVR -19.5±3.2%, p=0.04. A novel finding of this study was significant correlation of MRS-measured TG content with histological staining of TG of the myocardium, taken from endomyocardial biopsy during AVR. In DCM, myocardial TG was independently associated with LV dilatation and correlated significantly with hepatic TG, which suggests that both cardiac and hepatic steatosis might be a common feature in the failing heart. Additionally, although the hypertrophied heart is characterised by impaired perfusion, it is unknown if this is severe enough to translate into tissue deoxygenation and ischaemia. I assessed this by using adenosine vasodilator stress test and BOLD-CMR in patients with severe AS. It was found that AS patients had reduced perfusion (myocardial perfusion reserve index-MPRI 1.0±0.3 vs. controls 1.7±0.3, p<0.001), and blunted tissue oxygenation (blood-oxygen level dependent-BOLD signal intensity-SI change 4.8±9.6% vs. controls 18.2±11.6%, p=0.001) during stress. Importantly, there was a substantial improvement in perfusion and oxygenation towards normal after AVR, MPRI 1.5±0.4, p=0.005 vs. pre AVR and BOLD SI change 16.4±7.0%, p=0.014 vs. pre AVR. Overall, the work in this thesis supports the powerful role of CMR in assessing LV function and elucidating metabolic mechanisms in the hypertrophied and failing heart.
|
104 |
Is failure to achieve smoking cessation before treatment related to the patency of lower extremity after angioplasty?Wong, Lai-ting., 黃禮庭. January 2006 (has links)
published_or_final_version / Community Medicine / Master / Master of Public Health
|
105 |
Hope and life-struggle : patients' experiences with Transcatheter Aortic Valve ImplantationOlsson, Karin January 2016 (has links)
The overall aim of this thesis is to explore experiences and self-reported outcomes from Transcatheter Aortic Valve Implantation, TAVI, among people with severe aortic stenosis. The thesis includes four studies. Study I-II are based on interviews performed the day before TAVI and Qualitative Concept Analysis was used for analysis. Study III is based on interviews at six months’ follow-up and Grounded Theory was used for analysis. Study IV is quantitative and based on questionnaires at baseline and at six months’ follow-up. Nonparametric, descriptive statistics were used for the analysis. Study I described the vulnerable situation for patients with severe aortic stenosis before TAVI. They were facing death and at the same time struggling to cope with their symptoms and to maintain independent. TAVI offered hope but also caused uncertainty about the new method. Study II focused on the patients’ decision-making process. Three patterns were identified; ambivalent, obedient, and reconciled. The ambivalent patient is unsure of the value of treatment and aware of the risks; the obedient patient is unsure of the value of one's own decision and wants to leave the decision to others; the reconciled patient has reached a point where there is no choice anymore and is always sure that the decision to undergo TAVI is right. Study III offered a deeper understanding of the TAVI trajectory. A journey of balancing between hope and life-struggle was the core category of the analysis. Before TAVI patients felt threatened, but also experienced hope. The rehabilitation phase was described as demanding and depressing or surprisingly simple. At the six months’ followup patients described being pleased to return to life, however, many were still struggling with limitations. Study IV focused on quantifying the symptom burden, function and health related quality of life before and after TAVI. The results were reflected against that of patients treated with open surgery. Self-rated function and health related quality of life increased and symptoms were reduced at follow-up, but breathlessness and fatigue were still common. Conclusively, TAVI patients are struggling with limitations, both because of their comorbidities and because of their valve disease which also poses a threat to their lives. TAVI gives an opportunity to survive, to stay independent and to increase quality of life. To feel and preserve hope is essential for patients’ wellbeing, both before and during the recovery process.
|
106 |
Living with Aortic Stenosis: A Phenomenological Study of Patients' Experiences and Subsequent Health ChoicesHagen-Peter, Gayle Ann 01 January 2015 (has links)
Symptomatic aortic stenosis (AS) is an increasing phenomenon as more adults live longer. The gold standard for treating AS is surgical aortic valve replacement (SAVR). Frequently, as older individuals with AS often have multiple comorbidities, a SAVR is determined to be too high risk. Therefore, a less invasive treatment option is available, namely a transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve replacement (TAVR). Such biomedical procedures have encouraged life extension and the decision to intervene commonplace with the aging population. Without an intervention, significant debilitating symptoms affect a person's quality of life (QoL). Multiple quantitative studies evaluating QoL before and after a TAVI have been performed. However QoL has multiple attributes and is not a single construct. By limiting practice to these defined QoL measures, we exclude the human experience and what values individuals describe as important to them. The dilemma in the present medical model is influenced by two paradigms, evidence based medicine and patient centered medicine.
Some people opt not to have a TAVI. This study aims to understand what it is like living with aortic stenosis as perceived by the participant and to gain a more meaningful understanding of why some individuals with AS choose not to have this procedure performed. Using a convenience sample of patients who declined a TAVI, a telephone interview with the person focused on their perceived QoL and the implications determining not to pursue a TAVI. In this qualitative phenomenological design, open-ended questions included: 1) What is it like to live with Aortic Stenosis. 2) Why did you choose not to have the TAVI? Interviews will explore emerging themes. Advanced practice nurses are in ideal positions for performing research to gain greater insight on the complexity of people's health choices. As the incidence of AS occurs more frequently in the increasing aged population, TAVI offers a treatment option for those patients who are symptomatic with AS and are not surgical candidates. However, health care providers should focus on the illness, not the disease, and explore the patients' biopsychosocial values with their medical needs. The information gathered in this study will help guide heath care providers with offering holistic health care incorporating both paradigms of evidence based practice and patient centered medicine options on treatment for people with symptomatic AS.
|
107 |
Valor prognóstico dos peptídeos natriuréticos BNP e NT-proBNP na estratificação de risco dos pacientes com estenose aórtica grave / Prognostic value of natriuretic peptides BNP and NT-proBNP in risk stratification of patients with severe aortic stenosisKatz, Marcelo 03 July 2009 (has links)
INTRODUÇÃO: A estenose aórtica, doença valvar de grande prevalência, tem na avaliação clínica e ecocardiográfica as principais ferramentas para avaliação dos pacientes. Ferramentas auxiliares de avaliação são desejáveis e neste contexto surgem os peptídeos natriuréticos. Os peptídeos natriuréticos BNP e NT-proBNP podem ser usados como marcadores diagnósticos e prognósticos em diversas situações clínicas. Postulamos que os peptídeos pudessem ter papel diagnóstico, mas principalmente valor prognóstico em pacientes com estenose aórtica grave. OBJETIVO: primariamente, definir o papel prognóstico de sobrevida dos peptídeos natriuréticos BNP e NT-proBNP no acompanhamento prospectivo de uma população de pacientes com estenose aórtica grave. Secundariamente, comparar os níveis séricos de BNP e NT-proBNP entre pacientes com EAo grave assintomáticos e sintomáticos. MÉTODOS: Foram incluídos de forma consecutiva 66 pacientes com estenose aórtica grave, definida pela presença de gradiente médio de pressão transvalvar aórtica maior que 40 mmHg. Os critérios de exclusão foram fibrilação atrial, outra valvopatia, cardiopatia associada, infecções ativas, neoplasias, doenças auto-imunes ou inflamatórias, insuficiência renal e obesidade. Dos 66 pacientes incluídos, 76% eram sintomáticos (50/66). Os sintomas foram definidos como dispnéia aos esforços, síncope ou angina. Na inclusão, todos os pacientes foram submetidos à avaliação clínica inicial, realização de ecocardiograma e dosagem de BNP e NT-proBNP. Os pacientes sintomáticos recebiam a indicação de tratamento cirúrgico e os pacientes assintomáticos eram conduzidos clinicamente. Os pacientes foram acompanhados prospectivamente. O desfecho clínico avaliado foi óbito cardiovascular, definido por morte súbita, morte por insuficiência cardíaca e óbito peri-operatório. RESULTADOS: Os pacientes foram acompanhados por 869 + 397 dias. Houve 11 óbitos durante o acompanhamento. Na inclusão, os níveis de BNP e NT-proBNP foram similares em assintomáticos e sintomáticos: BNP 72 (41-175) pg/mL versus 104 (46-270) pg/mL; p = 0,275 e NT-proBNP 676 (235-1356) pg/mL vs. 871 (310-2230) pg/mL; p = 0,226. Houve diferença entre os níveis de BNP e NT-proBNP e classe funcional (p < 0,001 e p < 0,001, respectivamente). Através da curva ROC foi determinado um valor de corte de BNP (105 pg/mL) e NT-proBNP (1500 pg/mL) capazes de predizer classe funcional III e IV (New York Heart Association), com área sob a curva de 0,806 e 0,786 respectivamente. BNP e NT-proBNP foram preditores de mortalidade (p=0,007 e p=0,001 respectivamente). BNP > 105 pg/mL aumentou o risco de óbito cardiovascular de forma independente [OR= 6,3 (IC95%: 1,36 - 29,25)]. NT-proBNP > 1500 pg/mL aumentou o risco de óbito cardiovascular de forma independente [OR = 6,5 (IC95%: 1,73 - 24,63)]. CONCLUSÃO: O BNP e o NTproBNP foram preditores independentes de mortalidade em pacientes com estenose aórtica grave em um acompanhamento de quatro anos. O BNP e o NT-proBNP foram preditores de classe funcional III e IV (New York Heart Association) em pacientes com estenose aórtica grave. O BNP e o NT-proBNP não permitiram diferenciar pacientes sintomáticos de assintomáticos / BACKGROUND: Aortic valve stenosis is a high prevalent cardiac valve disease, in which clinical and echocardiographic parameters are the most common approach of diagnosis and risk evaluation. Complementary methods are desirable and the natriuretic peptides BNP and NT-proBNP, both diagnostic and prognostic markers in multiple clinical situations, could improve patient assessment. We postulate that these peptides may have diagnostic purpose, but mainly a prognostic value in patients with severe aortic stenosis. OBJECTIVE: primarily, define the survival prognostic role of natriuretic peptides BNP and NT-proBNP in monitoring a population of patients with severe aortic stenosis prospectively. Secondarily, compare the serum levels of BNP and NT-proBNP among patients with symptomatic and asymptomatic severe aortic stenosis. METHODS: 66 consecutive patients with severe aortic stenosis, defined by the presence of gradient mean transvalvular aortic pressure greater than 40 mmHg were included. Exclusion criteria were concomitant atrial fibrillation, other valve disease, other myocardiopathies, active infections, autoimmunity diseases, inflammatory diseases, neoplasia, renal failure or obesity. 76% of patients were symptomatic (50/66), defined as dyspnea on exertion, syncope or angina. All patients underwent initial clinical evaluation, echocardiography and BNP and NT-proBNP measurement. Symptomatic patients were referred for surgical treatment and asymptomatic patients were clinically managed. (Patients were followed up prospectively). The clinical outcome was cardiovascular death, defined by sudden death, death from heart failure and peri-operative death. RESULTS: Patients were followed up for 869 + 397 days. There were 11 deaths during followup. On admission, levels of BNP and NT-proBNP were similar in asymptomatic and symptomatic individuals: BNP 72 (41-175) pg / mL vs. 104 (46-270) pg / mL, p = 0.275 and NT-proBNP 676 (235-1356) pg / mL vs. 871 (310-2230) pg / ml, p = 0.226. There were differences between the levels of BNP and NT-proBNP and functional class (p <0.001 p <0.001, respectively). ROC-curve analysis demonstrated a cut-off value of BNP (105 pg / mL) and NT-proBNP (1500 pg / mL) capable of predicting NYHA functional class III and IV, with an area under the curve of 0.806 and 0.786 respectively. BNP and NT-proBNP could predict mortality (p = 0.007 and p = 0.001 respectively). BNP > 105 pg/mL independently increased the risk of cardiovascular death [OR = 6.3 (95% CI: 1.36 to 29.25)]. NT-proBNP > 1500 pg/mL independently increased the risk of cardiovascular death [OR = 6.5 (95% CI: 1.73 to 24.63)]. CONCLUSION: BNP and NT-proBNP were independent predictors of mortality in patients with severe aortic stenosis after a follow up of 4 years. BNP and NT-proBNP were predictors of NYHA functional class III and IV in patients with severe aortic stenosis. BNP and NT-proBNP alone did not distinguish symptomatic from asymptomatic patients
|
108 |
Tratamento das lesões intra-epiteliais cervicais de alto grau com cirurgia de alta freqüência em mulheres portadoras ou não do vírus da imunodeficiência humana / Treatment of intra-epithelial lesions of cervical high degree with surgery in high frequency bearers of women or no Virus Human ImmunodeficiencyMelli, Patrícia Pereira dos Santos 20 December 2005 (has links)
Introdução: Sabe-se que a elevada prevalência da infecção pelo HPV na população sexualmente ativa, associa-se ao desenvolvimento delesões intra-epiteliais cervicais de alto grau e de baixo grau (LIEAG e LIABG). A cirurgia dealta freqüência (CAF) veio contribuir para o tratamento da LIE, substituindo práticas invasivas e onerosas. A população contaminada pelo HPV é composta por pacientes imunocompetentes e imunodeprimidas, especialmente as infectadas pelo HIV, que poderão ter diferente resposta a esta cirurgia. Objetivos:Avaliar a efetividade da CAF no tratamento das LIEAG no colo uterino e a taxa de complicações tardias dessa modalidade terapêutica em pacientes portadoras ou não do HIV e avaliar se a infecção HIV favorece a persistência de LIEAG após a CAF. Pacientes e Métodos: Estudo observacional prospectivo longitudinal onde foram selecionadas 97 pacientes portadoras de LIEAGe tratadas com CAF divididas em dois grupos: 38 pacientes portadoras do HIV e 59 não infectadas por esse vírus, todas atendidas em Hospital Universitário de referência terciária. As pacientes foram submetidas a CAF e reavaliadas com coleta de colpocitologia e colposcopia com três, seis, nove e 12 meses após o procedimento. As taxas de efetividade da CAF consideraram a evolução da doença cervical ao longo do seguimento desses dois grupos de pacientes por um ano. Resultados:Após o seguimento de 12 meses foram observadas situações de cura (citologia e colposcopia normais), melhora (citologia e/ou comcolposcopia com sinais de infecção HPV ou LIEBG) ou de piora da LIEAG inicial (lesão microinvasora/invasora). Sendo assim, foram obtidos para as pacientes portadoras do HIV: 56,7% de cura; 32,4% de melhora e nenhum caso de piora após o tratamento inicial. Para as pacientes não portadoras do HIV os resultados foram: 75,8% de cura; 13,8% demelhora e 1,7% de piora, indicando desfecho clínico mais favorável entre as pacientes não portadoras do HIV (X 2 , p= 0,02). As taxas de estenose de canal cervical entre as pacientes portadoras do HIV (13,5%) não foram estatisticamente diferentes daquelas observadas entre as pacientes não portadoras do HIV (10,5%). A excisão completa da LIE que motivou a CAF ocorreu em 69 (71,2%) pacientes. Entretanto, 21 (21,7%) mulheres tiveram excisão incompleta com margens da peça cirúrgica comprometida pela LIE. Dessas 21 pacientes que apresentaram margens da peça cirúrgica comprometidas apenas cinco tiveram necessidade de novo tratamento. Também foram submetidas a novo tratamento três das mulheres que tiveram margens cirúrgicas livres da peça excisada e uma paciente com a margemcirúrgica carbonizada. Conclusões: Não foi encontrada diferença estatisticamente significativa entre os dois grupos estudados em relação ao número de complicações após a realização da CAF e também na necessidade de novo tratamento no caso de mulheres portadoras do HIV. Entretanto, o desfecho clínico favorável (cura e melhora) para essa população estudada foi significativamente melhor para as pacientes não portadoras do HIV que para as infectadas por esse vírus após um ano de seguimento pós-CAF. A recidiva da LIEAG é mais freqüente em pacientes com margens cirúrgicas comprometidas, independente da presença da infecção pelo HIV. / Introduction: It is known that the high prevalence of HPV infection in the sexually active population is associated with the development of high and low-grade squamous intraepithelial lesions (HSIL and LSIL). Loop electrosurgical excision procedure (LEEP) has contributed to the treatment of SIL, replacing invasive and expensive procedures. The population contaminated with HPV consists of immunocompetent and immunodepressed patients, especially HIV-infected patients, who may respond differently to this surgery Objectives:To assess the effectiveness of LEEP in the treatment of HSIL in the uterine cervix and the rate of late complications of this therapeutic modality in patients infected or not with HIV and to determine whether HIV infection predisposes to the persistence of HSIL after LEEP. Patients and Methods: This was a prospective longitudinal observational study conducted on 97 patients with HSIL and treated with LEEP who were divided into two groups: 38 HIV-infected and 59 non-HIV-infected patients attended at a tertiary reference University Hospital. The patients were submitted to LEEP and re-evaluated bycolpocytology and colposcopy at three, six, nine and 12 months after the procedure.The rates of LEEP effectiveness were determined on the basis of the evolution of cervical disease along a one year follow-up of the two groups of patients Results:After a follow-up of 12 months, situations of cure (normal cytology and colposcopy), improvement (cytology and/or colposcopy with signs of HPV infection or HSIL) or of worsening of the original HSIL (microinvasive/invasive lesion) were observed. On this basis, the followingresults were obtained for HIV-infected patients: 55.2% of cure, 34.3% of improvement and no case of worsening after the initial treatment. For non-HIV-infected patients, the results were: 75.4% of cure, 14.1% of improvement and 1.7% of worsening, indicating a more favorable clinical outcome among non-HIV-infected patients (X 2 , p= 0.02). The rates of cervical canal stenosis among HIV-infected patients (13.5%) did not differ significantly from those among non-HIV-infected patients (10.5%). Complete excision of the SIL that motivated LEEP occurred in 69 (71.2%) patients. However, in 21 (21.7%) women, excision was incomplete, with SIL involvement of the margins of the surgical piece. Of these 21 patients with compromised surgical piece margins, only five required new treatment. Three of the women whose surgical margins were freeof disease and one patient with a carbonized surgical margin were also submitted to new treatment. Conclusions:No statistically significant difference was detected between the two groups regarding the number of complications after LEEP or also regarding the need for new treatment among HIV-infected women. However, a favorable clinical outcome (cure and improvement) for this population was significantly better for non-HIV-infected patients than for HIV-infected patients after one year of post-LEEP follow-up. HSIL recurrence was more frequent among patients with involved surgical margins regardless of the presence of HIV infection.
|
109 |
"Hiperplasia intimal arterial decorrente de um modelo experimental de estenose aórtica intrínseca: estudo morfológico, morfométrico e ultraestrutural" / Arterial intimal hyperplasia with intraluminal hemispherical plug stenosis: a morphologic and ultrastructural studyBeneli, Cristina Tonin 24 September 2004 (has links)
O objetivo do presente trabalho foi avaliar a morfologia e a ultraestrutura da hiperplasia intimal arterial decorrente de um modelo de estenose aórtica experimental, através da inserção de um pino de acrílico no orifício da artéria renal esquerda. Realizamos um estudo morfológico e ultraestrutural em 64 ratos Wistar, machos, com peso médio de 250 g, divididos em 4 subgrupos de acordo com o dia da eutanásia (1, 7, 15 e 30 dias de pós-operatório). O segmento da aorta envolvendo o pino foi retirado e estudado com diferentes protocolos para: microscopia óptica de alta resolução, microscopia eletrônica de transmissão e de varredura. Uma trombose se formou ao redor do pino 24 horas após a cirurgia, mostrando sinais de organização com 7 dias. Com 15 dias, uma hiperplasia intimal adjacente à base do pino foi visualizada. Esta alteração permaneceu com 30 dias de pós-operatório. Este espessamento era caracterizado principalmente por células musculares lisas provenientes da camada muscular média. A obstrução gera alterações hemodinâmicas locais com repercussão sobre as células endoteliais localizadas próximas à base do pino. Esses achados são discutidos. / Objective: To study the light and electron microscopy of intimal hyperplasia induced by experimental aortic stenosis after insertion of a plug into the aorta through the left renal artery. Methods: Sixty-four Wistar male rats, weighing an average of 250g, were allocated into two groups: group control, sham-operated, and group experimental, operated. The animals were killed on days 1, 7, 15, and 30 after surgery. The fragments of aorta implicating the plug were excised and studied using high resolution light microcopy and transmission and scanning electron microscopy. Results and Conclusions: A thrombus was observed around the plug 24 hours after surgery, organized at day 7. An intimal hyperplasia could be observed closed to the basis of the plug 15 and 30 days after surgery. The intimal thickening detected was mainly composed of smooth muscle cells migrated from the medial layer of the aorta intermixed with extracellular matrix. Moreover, the endothelial cells around the plug lost their orientation. Theses findings are discussed.
|
110 |
Efetividade e custo do tratamento invasivo da estenose valvar aórticaTognon, Alexandre Pereira January 2016 (has links)
O expressivo número de brasileiros que necessitam correção anatômica da estenose valvar aórtica acentuada e que não realizam cirurgia de substituição valvar devido ao risco proibitivo justifica a necessidade de investigação, tanto da efetividade no cenário clínico real quanto dos custos impostos ao Sistema Único de Saúde e aos planos de saúde suplementar brasileiros pela incorporação do implante transcateter de valva aórtica, que tem se demonstrado efetivo mas oneroso, internacionalmente. No primeiro artigo da tese, avaliaram-se os desfechos intra-hospitalares, a sobrevida e o reembolso pela internação hospitalar de 41 pacientes com idade média de 78,7 ± 6,3 anos, estenose valvar aórtica acentuada, com recusa cirúrgica e decisão multidisciplinar por tratamento transcateter entre outubro de 2010 e outubro de 2015. Os sujeitos foram seguidos prospectivamente por um período mediano de 15,2 (4,5 – 25,6) meses e a sobrevida estimada em 1 e 2 anos foi de 73,2% e 64,1%, respectivamente. Identificou-se que hipertensão pulmonar e revascularização miocárdica cirúrgica prévia estavam independentemente associadas à menor sobrevida. O valor mediano reembolsado pelos pacientes atendidos pelo Sistema Único de Saúde foi R$ 108.634,34 (101.051,05 – 127.255,27) e R$ 115.126,77 (94.603,21 – 132.603,01) para aqueles internados por planos de saúde suplementar ou particulares, sendo o respectivo valor mediano reembolsado pela prótese valvar de R$ 82.000,00 (82.000,00 – 95.450,00) e 84.050,00 (75.000,00 – 92.400,00) Em um grupo de 585 procedimentos de troca valvar aórtica cirúrgica em indivíduos com idade ≥ 60 anos, realizados entre janeiro de 2010 e dezembro de 2015 na mesma instituição, a mortalidade intra-hospitalar estava associada à idade e foi de 5,9% naqueles com idade entre 60 e 70 anos, 10,8% entre 70 e 80 anos e de 22,2% ≥ 80 anos. O reembolso mediano foi de R$ 14.035,96 (11.956,11 – 16.644,90) para os internados pelo Sistema único de Saúde e R$ 20.273,97 (15.358.03 – 32.815,49) pelos planos de saúde suplementar ou particulares. No segundo artigo da tese, identificou-se que do total de 819 pacientes consecutivamente incluídos no Registro Brasileiro de Implante de Bioprótese Aórtica por Cateter entre janeiro de 2008 e outubro de 2015, 15 (1,8%) sofreram perfuração do ventrículo esquerdo. Os pacientes que apresentaram perfuração eram mais idosos (85,4 ± 6,3 vs. 81,5 ± 7,3 anos, p=0,038), predominantemente mulheres (80,0% vs. 50,5%, p=0,024), apresentavam maior fração de ejeção (67,3 ± 7,8% vs. 58,6 ± 15,0%, p=0,001), menor massa ventricular esquerda (203,9 ± 47,1g vs. 247,6 ± 78,7g, p=0,039) e menor altura do tronco da coronária esquerda (11,2 ± 5,4mm vs. 14,0 ± 3,3mm, p=0,034). Os preditores independentes de perfuração do ventrículo esquerdo foram idade e fração de ejeção. No terceiro artigo, descreve-se um caso de ablação septal para tratamento de miocardiopatia hipertrófica obstrutiva assimétrica para posterior implante transcateter de valva aórtica, sugerindo que esta seja uma estratégia factível quando da concomitância dessas duas condições Em conclusão, os desfechos do tratamento transcateter da estenose valvar aórtica acentuada em pacientes inoperáveis são compatíveis com aqueles do cenário idealizado dos ensaios clínicos randomizados, apesar de estarem associados a custos maiores que os anteriormente estimados por painéis de especialistas. O tratamento cirúrgico, por sua vez, apresentou mortalidade maior que aquela idealizada ou relatada como usual. A hipercinesia do ventrículo esquerdo pode favorecer o trauma determinado pelo guia metálico, posicionado em seu interior para realização do procedimento, estando a fração de ejeção independentemente associada à chance de perfuração. Ainda, a ablação septal por álcool eletiva, anterior ao implante transcateter da valva aórtica, é uma abordagem factível para pacientes com hipertrofia ventricular esquerda assimétrica obstrutiva associada à estenose valvar aórtica. / The expressive number of Brazilians who require an anatomic correction for severe aortic valve stenosis and who do not undergo valvar replacement surgery due to prohibitive risk justifies the need to investigate both the effectiveness in the real clinical scenario and the costs imposed to the Public Health System and the Supplementary Health System for the incorporation of the transcatheter aortic valve implantation, which has been shown to be effective but onerous, internationally. In the first article of the thesis, the in-hospital outcomes, long-term survival and reimbursement for 41 patients, with a mean age of 78.7 ± 6.3 years, sever aortic valve stenosis, with surgical refusal and multidisciplinary decision for transcatheter treatment, between October 2010 and October 2015 are described. Subjects were prospectively followed for a median period of 15.2 (4.5 - 25.6) months and the estimated survival at 1 and 2 years was 73.2% and 64.1%, respectively. It was identified that pulmonary hypertension and previous coronary artery bypass grafting were independently associated with lower survival. Median reimbursed values by the Public Health System was R$ 108,634.34 (101,051.05 - 127,255.27) and by supplementary health plans was R$ 115,126.77 (94,603.21 - 132,603.01). The respective median values reimbursed for the valve prosthesis was R$ 82,000.00 (82,000.00 - 95,450.00) and 84,050.00 (75,000.00 - 92,400.00) In a group of 585 surgical aortic valve replacement procedures in subjects aged ≥ 60 years, performed between January 2010 and December 2015 in the same institution, in-hospital mortality was associated with age and was 5.9% in those with age between 60 and 70 years, 10.8% between 70 and 80 years and 22.2% in ≥ 80 years. The median reimbursement was R$ 14,035.96 (11,956.11 - 16,644.90) for those hospitalized by the Public Health System and R$ 20,273.97 (15,358.03 - 32,815.49) by supplementary or private health plans. In the second article of the thesis, it was identified that of the total of 819 patients consecutively included in the Brazilian Registry of Aortic Bioprosthesis Implantation by Catheter (RIBAC) between January 2008 and October 2015, 15 (1.8%) suffered perforation of the left ventricle. Patients with perforation were older (85.4 ± 6.3 vs. 81.5 ± 7.3 years, p=0.038), predominantly women (80.0% vs. 50.5%, p=0.024), had a higher ejection fraction (67.3 ± 7.8% vs. 58.6 ± 15.0%, p=0.001), lower left ventricular mass (203.9 ± 47.1g vs. 247.6 ± 78, 7g, p=0.039) and shorter distance between the aortic annulus and the left main coronary artery ostium (11.2 ± 5.4mm vs. 14.0 ± 3.3mm, p=0.034). The independent predictors of left ventricular perforation were age and ejection fraction. In the third article, a case of septal ablation was described for the treatment of asymmetric obstructive hypertrophic cardiomyopathy for posterior transcatheter aortic valve implantation, suggesting that this is a feasible strategy when these two conditions are concomitant In conclusion, the outcomes of transcatheter treatment of severe aortic stenosis in inoperable patients are compatible with those in the ideal scenario of randomized clinical trials, although they are associated with higher costs than previously estimated by expert panels. Surgical treatment, on the other hand, presented higher mortality than that idealized or reported as usual. The left ventricle hyperkinesia may favor the trauma determined by the metallic guide, positioned inside it to perform the procedure, the ejection fraction being independently associated with the chance of perforation. Furthermore, elective alcohol septal ablation, prior to transcatheter aortic valve implantation, is a feasible approach for patients with obstructive asymmetric left ventricular hypertrophy associated with aortic valve stenosis.
|
Page generated in 0.0497 seconds